Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 33.78
+0.02 (0.06%)
May 7, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 11.86 billion as of May 7, 2026. Its market cap has decreased by -20.54% in one year.
Market Cap
11.86B
Enterprise Value
9.85B
Revenue
1.90B
Ranking
n/a
PE Ratio
n/a
Stock Price
33.78
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 11.86B, a decrease of -42.53%. That is a compound annual growth rate of -9.46%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 6, 2026 | 11.86B | -9.21% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascletis Pharma | 17.51B |
| Ascentage Pharma Group International | 16.11B |
| Nanjing Leads Biolabs | 15.67B |
| CStone Pharmaceuticals | 13.70B |
| CARsgen Therapeutics Holdings | 11.84B |
| HBM Holdings | 10.75B |
| Alphamab Oncology | 9.71B |
| Lepu Biopharma | 9.44B |